The funding round was led by Gresham House Ventures with backing from Balderton Capital, Eka Ventures, and Wavemaker360.
"The biggest bottleneck in healthcare isn't cost; it's access. Specialists are concentrated in a handful of postcodes; patients aren't. 32Co and Aerox have already brought expert dental treatments to areas of the UK where such treatments were inaccessible, proving the concept that specialist care could be democratised if the right technology layer existed underneath it,"
The Series A round was led by Voyager Ventures to fund the construction of a new production facility in the Thames Valley.
"For sixty years, VLEO has been treated as too hostile an environment for commercial satellites — but it is in fact the most valuable empty real estate in space. Today, no one in the industry has a reliable, affordable, and fast way to fly payloads into very low Earth orbit. We built our NEO-1 satellite to do exactly that,"
The round was led by DN Capital with participation from Vi Partners, Framework Venture Partners, and Atlassian Ventures.
"Revenue teams have systems of record and systems of intelligence. What they don't have is a system of action – one that understands their unique commercial context and does the work. Dashboards weren't wrong; they were incomplete. The next leap comes from agents that close the loop."
Albion VC led the Series A round to support nationwide clinic expansion and international growth.
"The healthcare supply-demand gap remains a major challenge, with over 390,000 people waiting for treatable MSK care in England alone. Finn, Ric and the team have proven that autonomous care pathways can deliver strong outcomes at scale. They’ve earned NHS trust, navigated complex regulations, and built a service that improves access to care. Having proven the model in MSK, we believe the opportunity ahead is far larger,"
The oversubscribed round was co-led by IQ Capital and Molten Ventures to expand the company's immune profiling platform.
"When we first invested in IMU in 2024, we believed deep immune profiling combined with AI could transform precision medicine. Since then, the team has consistently delivered. The immune system sits at the heart of almost every disease, and IMU’s ability to analyse it at this resolution could redefine how treatments are matched to patients. We’re proud to be IMU’s largest shareholder and excited to support the company’s next phase of growth."
